Ben J Dugan

Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

Jennifer L. Mason, P. Dobrzanski, B. Ruggeri, 2011, The Journal of Immunology.

Depletion of Autoreactive Plasma Cells and Treatment of Lupus Nephritis in Mice Using CEP-33779, a Novel, Orally Active, Selective Inhibitor of JAK2

Jennifer L. Mason, P. Dobrzanski, B. Ruggeri, 2011, The Journal of Immunology.

A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.

Jennifer L. Mason, Pawel Dobrzanski, Bruce D. Dorsey, 2012, Journal of medicinal chemistry.

Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Andrew V. Anzalone, Jason P. Burke, B. Ruggeri, 2011, Bioorganic & medicinal chemistry letters.

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis

P. Dobrzanski, B. Ruggeri, D. Gingrich, 2011, Arthritis research & therapy.

Novel Macrocyclic Antagonists of the Calcitonin Gene-Related Peptide Receptor: Design, Realization, and Structural Characterization of Protein-Ligand Complexes.

M. Congreve, J. Mason, A. Bortolato, 2022, ACS chemical neuroscience.